Use of direct oral anticoagulants in kidney diseases
DOI:
https://doi.org/10.22141/2307-1257.14.1.2025.507Keywords:
direct oral anticoagulants, apixaban, dabigatran, edoxaban, nephrotic syndrome, rivaroxaban, thromboembolism, thrombosis, chronic kidney diseaseAbstract
The literature review analyzes current data on the pharmacokinetics, pharmacodynamics of direct oral anticoagulants, their use in nephrotic syndrome, at different stages of chronic kidney disease complicated by atrial fibrillation, venous thrombosis, and in comorbid oncological pathology.
Downloads
References
Saeed Z, Sirolli V, Bonomini M, Gallina S, Renda G. Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients. Int J Mol Sci. 2024 Aug 9;25(16):8705. doi: 10.3390/ijms25168705.
Wu T, Tang LV, Hu Y. Venous Thromboembolism in Kidney Diseases and Genetic Predisposition. Kidney Dis (Basel). 2022 Apr 11;8(3):181-189. doi: 10.1159/000523777.
Wang SS, Tang H, Ng HY, Lian JJ, Javaid MM. Thromboembolic phenomena in patients with nephrotic syndrome: pathophysiology, risk factors, prophylaxis and treatment. Br J Hosp Med (Lond). 2024 Jan 2;85(1):1-10. doi: 10.12968/hmed.2023.0354.
Barnes GD, Ageno W, Castellucci LA, et al. Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation. J Thromb Haemost. 2023 May;21(5):1381-1384. doi: 10.1016/j.jtha.2023.02.008.
Sánchez-Fuentes A, Rivera-Caravaca JM, López-Gálvez R, Marín F, Roldán V. Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Front Cardiovasc Med. 2022 Jan 17;8:787235. doi: 10.3389/fcvm.2021.787235.
Ashton V, Kerolus-Georgi S, Moore KT. The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. J Clin Pharmacol. 2021 Aug;61(8):1010-1026. doi: 10.1002/jcph.1838.
Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells. 2022 Oct 13;11(20):3214. doi: 10.3390/cells11203214.
Clinical Excellence Commission. Direct Oral Anticoagulant: DOAC Guidelines. Version 1.1. Sydney: Clinical Excellence Commission; 2025. 35 p.
Qi X, Shao X, editors. Anticoagulation - an update. London, UK: Intech Open; 2024. 166 p. doi: 10.5772/intechopen.111193.
Levy JH, Shaw JR, Castellucci LA, et al. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2024 Oct;22(10):2889-2899. doi: 10.1016/j.jtha.2024.07.009.
Olie RH, Winckers K, Rocca B, Ten Cate H. Oral Anticoagulants Beyond Warfarin. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:551-575. doi: 10.1146/annurev-pharmtox-032823-122811.
Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018 Feb;16(2):209-219. doi: 10.1111/jth.13912.
Willcox A, Ho L, Jones D. Implications of direct oral anticoagulation and antiplatelet therapy in intensive care. Crit Care Resusc. 2020 Sep;22(3):181-188. doi: 10.1016/S1441-2772(23)00384-8.
Exner T, Rigano J, Favaloro EJ. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. Int J Lab Hematol. 2020 Jun;42(Suppl 1):41-48. doi: 10.1111/ijlh.13196.
Moser KA, Smock KJ. Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):129-133. doi: 10.1182/hematology.2021000241.
Margetić S, Goreta SŠ, Ćelap I, Razum M. Direct oral anticoagulants (DOACs): From the laboratory point of view. Acta Pharm. 2022 Oct 18;72(4):459-482. doi: 10.2478/acph-2022-0034.
Bejjani A, Khairani CD, Assi A, et al. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 Jan 23;83(3):444-465. doi: 10.1016/j.jacc.2023.10.038.
Padrini R. Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):1-12. doi: 10.1007/s13318-018-0501-y.
Atzemian N, Kareli D, Ragia G, Manolopoulos VG. Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review. Front Pharmacol. 2023 Sep 29;14:1244098. doi: 10.3389/fphar.2023.1244098.
Russo V, Fabiani D. Put out the fire: The pleiotropic anti-inflammatory action of non-vitamin K oral anticoagulants. Pharmacol Res. 2022 Aug;182:106335. doi: 10.1016/j.phrs.2022.106335.
Gori AM, Camilleri E, Bertelli A, et al. Pleiotropic effects of anti-thrombotic therapies: have direct oral anticoagulants any anti-inflammatory effect? Bleeding, Thrombosis and Vascular Biology. 2022;1(3):1-9.doi: 10.4081/btvb.2022.50.
Jannati S, Patnaik R, Banerjee Y. Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling. Int J Mol Sci. 2024 Aug 10;25(16):8727. doi: 10.3390/ijms25168727.
Mele M, Mele A, Imbrici P, et al. Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis. Molecules. 2024 Jun 4;29(11):2651. doi: 10.3390/molecules29112651.
Mezue K, Ram P, Egbuche O, Menezes RG, Lerma E, Rangaswami J. Anticoagulation-related nephropathy for the internist: a concise review. Am J Cardiovasc Dis. 2020 Oct 15;10(4):301-305.
Nonaka E, Takashima T, Matsumoto K, Fukuda M, Rikitake S, Miyazono M. Warfarin-related nephropathy: A case report of a delayed renal function improvement. Clin Case Rep. 2021 May 19;9(5):e04105. doi: 10.1002/ccr3.4105.
Brittanee S, Matthew D, Hannah S, Gregory G. Warfarin Related Kidney Damage: A Confusing Case of Thrombophlebitis Masquerading as Infection. J Prim Care Community Health. 2023 Jan-Dec;14:21501319231159978. doi: 10.1177/21501319231159978.
Mitsuboshi S, Niimura T, Zamami Y, Ishizawa K. Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database. Br J Clin Pharmacol. 2021 Jul;87(7):2977-2981. doi: 10.1111/bcp.14688.
Iwafuchi Y, Ito Y, Imai N, Oyama Y, Narita I. Dabigatran-related Nephropathy Complicated by Tubulointerstitial Nephritis in a Patient with a Normal Renal Function and Undiagnosed IgA Nephropathy. Intern Med. 2024 Jun 1;63(11):1615-1621. doi: 10.2169/internalmedicine.2628-23.
Magbri A, Keshani B, Hernandez PA. Frequently Missed, Never Dismissed: Anticoagulant-Related Nephropathy. Open Journal of Nephrology. 2022;12(3):262-266. doi:10.4236/ojneph.2022.123027.
Piedade A, Domingues P, Inácio A, et al. Anticoagulant-related nephropathy: An atypical case with two episodes. NefroPlus. 2023;15(1):102-106. doi: 10.1016/S1888-9700(24)00022-7.
Chen S, Liao D, Yang M, Wang S. Anticoagulant-related nephropathy induced by direct-acting oral anticoagulants: Clinical characteristics, treatments and outcomes. Thromb Res. 2023 Feb;222:20-23. doi: 10.1016/j.thromres.2022.12.002.
Dasgupta A, Mikhalina G, Satoskar AA, et al. Clinical Outcomes in Patients With Biopsy Proven Anticoagulant-Related Nephropathy. Kidney Int Rep. 2023 Apr 24;8(7):1445-1448. doi: 10.1016/j.ekir.2023.04.014.
Wojtowicz D, Tomaszuk-Kazberuk A, Małyszko J, Koziński M. Hematuria and other kinds of bleedings on non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: an updated overview on occurrence, pathomechanisms and management. Wiad Lek. 2020;73(11):2528-2534.doi: 10.36740/WLek202011135.
Bhatt NR, Davis NF, Nolan WJ, et al. Incidence of Visible Hematuria Among Antithrombotic Agents: A Systematic Review of Over 175,000 Patients. Urology. 2018 Apr;114:27-32. doi: 10.1016/j.urology.2017.11.023.
Parker K, Ragy O, Hamilton P, Thachil J, Kanigicherla D. Thromboembolism in nephrotic syndrome: controversies and uncertainties. Res Pract Thromb Haemost. 2023 Aug 9;7(6):102162. doi: 10.1016/j.rpth.2023.102162.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
Parker K, Choudhuri S, Lewis P, Thachil J, Mitra S. UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey. BMC Nephrol. 2023 Jan 12;24(1):9. doi: 10.1186/s12882-022-03041-w.
Lin R, McDonald G, Jolly T, Batten A, Chacko B. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney Int Rep. 2019 Dec 12;5(4):435-447. doi: 10.1016/j.ekir.2019.12.001.
Kelddal S, Hvas AM, Grove EL, Birn H. Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases. BMC Nephrol. 2022 Sep 5;23(1):305. doi: 10.1186/s12882-022-02929-x.
Van Meerhaeghe T, Cez A, Dahan K, et al. Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome. TH Open. 2022 Oct 7;6(4):e299-e303. doi: 10.1055/a-1920-6224.
Tijani A, Coons EM, Mizuki B, et al. Direct Oral Anticoagulants versus Warfarin for Venous Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Retrospective Cohort Study. Ann Pharmacother. 2023 Jul;57(7):787-794. doi: 10.1177/10600280221129348.
Nissar SM, Kuchay AA, Mir TH, Goud LN, Latief M. Direct Oral Anticoagulants in Nephrotic Syndrome: Our Experience and Literature Review. Indian J Nephrol. 2024 Mar-Apr;34(2):169-171. doi: 10.4103/ijn.ijn_317_22.
Mullen DB, Di Renzo BM, Walroth TA,Beam DM, Kline JA. Case Report: Possible Rivaroxaban Failure in Patient with Nephrotic Syndrome Discussing Anticoagulation in Nephrotic Syndrome. Clin Case Rep Int. 2021;5(1):1206. doi: 10.25107/2638-4558.1206.
Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2020 Apr;97(4):664-675. doi: 10.1016/j.kint.2019.11.027.
Ktenopoulos N, Sagris M, Theofilis P, Lionaki S, Rallidis LS. Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse. Front Biosci (Schol Ed). 2022 Jul 21;14(3):21. doi: 10.31083/j.fbs1403021.
Gadde S, Kalluru R, Cherukuri SP, Chikatimalla R, Dasaradhan T, Koneti J. Atrial Fibrillation in Chronic Kidney Disease: An Overview. Cureus. 2022 Aug 7;14(8):e27753. doi: 10.7759/cureus.27753.
Yasuoka R, Sakurane H, Okune M, et al. Changes in estimated glomerular filtration rate before and after the first visit for atrial fibrillation. BMC Nephrol. 2024 Jan 3;25(1):9. doi: 10.1186/s12882-023-03449-y.
Airy M, Schold JD, Jolly SE, et al. Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation. Am J Nephrol. 2018;48(1):36-45. doi: 10.1159/000491023.
Lucà F, Oliva F, Abrignani MG, et al. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios. J Clin Med. 2023 Sep 13;12(18):5955. doi: 10.3390/jcm12185955.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
Dhaese SAM, De Vriese AS. Oral Anticoagulation in Patients with Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation. Mayo Clin Proc. 2023 May;98(5):750-770. doi: 10.1016/j.mayocp.2023.01.007.
De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant. 2022 Oct 19;37(11):2072-2079. doi: 10.1093/ndt/gfab060.
Heine GH, Brandenburg V, Schirmer SH. Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. Dtsch Arztebl Int. 2018 Apr 27;115(17):287-294. doi: 10.3238/arztebl.2018.0287.
Albright RC Jr. Anticoagulating CKD Patients With Atrial Fibrillation: Are We Asking the Right Questions? Mayo Clin Proc. 2023 May;98(5):653-654. doi: 10.1016/j.mayocp.2023.03.010.
Sakai T, Motoki H, Fuchida A, et al. Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists. Heart Vessels. 2022 Jul;37(7):1232-1241. doi: 10.1007/s00380-022-02027-w.
Welander F. Anticoagulants in Kidney Disease. PhD diss. Umeå, Sweden : Umeå University; 2023.85 p.
Yao X, Inselman JW, Ross JS, et al. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2020 Oct;13(10):e006515. doi: 10.1161/CIRCOUTCOMES.120.006515.
Harrington J, Carnicelli AP, Hua K, et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. Circulation. 2023 Jun 6;147(23):1748-1757. doi: 10.1161/CIRCULATIONAHA.122.062752.
Li Y, Wu S, Zhou J, Zhang J. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis. Thromb J. 2024 Apr 29;22(1):40. doi: 10.1186/s12959-024-00608-5.
Chantrarat T, Hauythan S. The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation. Int J Cardiol Heart Vasc. 2021 Jul 31;35:100844. doi: 10.1016/j.ijcha.2021.100844.
Joglar JA, Chung MK, Armbruster AL. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2024;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017.
Van Gelder IC, Rienstra M, Bunting KV, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176.
Elenjickal EJ, Travlos CK, Marques P, Mavrakanas TA. Anticoagulation in Patients with Chronic Kidney Disease. Am J Nephrol. 2024;55(2):146-164. doi: 10.1159/000535546.
Niehues P, Wolfes J, Wegner FK, Ellermann C, Rath B, Eckardt L. Use of direct oral anticoagulants in patients on chronic hemodialysis: Contemporary appraisal on the role for patients with atrial fibrillation. Trends Cardiovasc Med. 2024 Oct;34(7):446-450. doi: 10.1016/j.tcm.2023.11.005.
Eikelboom J, Floege J, Thadhani R, Weitz JI, Winkelmayer WC. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int. 2021 Dec;100(6):1199-1207. doi: 10.1016/j.kint.2021.08.028.
Welander F, Renlund H, Själander A. Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants. Clin Kidney J. 2024 Jul 5;17(8):sfae206. doi: 10.1093/ckj/sfae206.
Barnes GD, Wright Nunes JA. Stroke prevention in atrial fibrillation with chronic kidney disease: a delicate balance of efficacy and safety considerations. Res Pract Thromb Haemost. 2024 Mar 15;8(2):102370. doi: 10.1016/j.rpth.2024.102370.
Kyriakoulis I, Adamou A, Stamatiou I, et al. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis. Eur J Intern Med. 2024 Jan;119:45-52. doi: 10.1016/j.ejim.2023.08.020.
Kuno T, Takagi H, Ando T, et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020 Jan 28;75(3):273-285. doi: 10.1016/j.jacc.2019.10.059.
Ballegaard ELF, Olesen JB, Kamper AL, et al. Oral anticoagulation for stroke prevention in atrial fibrillation and advanced kidney disease. Res Pract Thromb Haemost. 2024 Feb 15;8(2):102350. doi: 10.1016/j.rpth.2024.102350.
Kim DG, Kim SH, Park SY, et al. Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national population-based study. Clin Kidney J. 2024 Feb 13;17(2):sfae029. doi: 10.1093/ckj/sfae029.
Sinha T, Mayow AH, Abedin TT, et al. Comparison of Effectiveness and Safety of Direct-Acting Oral Anticoagulants and Vitamin K Agonists in Patients With Atrial Fibrillation and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. Cureus. 2024 Apr 2;16(4):e57447. doi: 10.7759/cureus.57447.
Vallini V, Andreini R, Sibilia G, et al. Warfarin-induced calciphylaxis-related skin ulceration in patients with end-stage renal disease: case report and literature review. Journal of Wound Care. 2024;33(8):13. doi: 10.12968/jowc.2022.0218.
Rupinder K, Sindhu Y, Saikiran M, Bhoomi S, Nowoghomwenma IC. A Difficult Case of Calciphylaxis: Continuous Warfarin Use in a Patient with Calciphylaxis. Journal of the American Society of Nephrology. 2024;35(10 Suppl):10.1681. doi: 10.1681/ASN.20242mq9jr6z.
Alasmari MM, Alsheikh MY, Metwali HH. Successful Treatment Using Apixaban in a Patient on Hemodialysis with Uremic Calciphylaxis. Clin Cosmet Investig Dermatol. 2022 Oct 28;15:2329-2333. doi: 10.2147/CCID.S382503.
Chen C, Cao Y, Zheng Y, et al. Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. Cardiovasc Drugs Ther. 2021 Apr;35(2):273-281. doi: 10.1007/s10557-021-07144-8.
Chandrasegaram A, Peters CD. The use of non-vitamin K oral anticoagulants in dialysis patients-A systematic review. Semin Dial. 2022 Nov;35(6):463-480. doi: 10.1111/sdi.13098.
Law MM, Tan SJ, Wong MCG, Toussaint ND. Atrial Fibrillation in Kidney Failure: Challenges in Risk Assessment and Anticoagulation Management. Kidney Med. 2023 Jun 19;5(9):100690. doi: 10.1016/j.xkme.2023.100690.
Kessler A, Kolben Y, Puris G, et al. Direct Oral Anticoagulants in Special Patient Populations. J Clin Med. 2023 Dec 29;13(1):216. doi: 10.3390/jcm13010216.
Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature. Eur J Haematol. 2019 Apr;102(4):312-318. doi: 10.1111/ejh.13208.
Fu EL, Desai RJ, Paik JM, et al. Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study. Am J Kidney Dis. 2024 Mar;83(3):293-305.e1. doi: 10.1053/j.ajkd.2023.08.017.
Mavrakanas TA, Garlo K, Charytan DM. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1146-1154. doi: 10.2215/CJN.11650919.
Reinecke H, Engelbertz C, Bauersachs R, et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 2023 Jan 24;147(4):296-309. doi: 10.1161/CIRCULATIONAHA.122.062779.
Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2019 Feb 7;14(2):278-287. doi: 10.2215/CJN.02170218.
Goto S, Haas S, Ageno W, et al.; GARFIELD-VTE Investigators. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Netw Open. 2020 Oct 1;3(10):e2022886. doi: 10.1001/jamanetworkopen.2020.22886.
Zhan Y, Fu X, Bi W, Li G. Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2024 Dec;46(2):2431149. doi: 10.1080/0886022X.2024.2431149.
Singh J, Khadka S, Solanki D, et al. Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States. SAGE Open Med. 2021 Jun 3;9:20503121211022996. doi: 10.1177/20503121211022996.
Becattini C, Bauersachs R, Maraziti G, et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica. 2022 Jul 1;107(7):1567-1576. doi: 10.3324/haematol.2021.279072.
Morán LO, Mateo FJP, Balanyà RP, et al. SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023). Clin Transl Oncol. 2024 Nov;26(11):2877-2901. doi: 10.1007/s12094-024-03605-2.
Cohen AT, Noxon V, Dhamane AD, et al. Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal disease. Curr Med Res Opin. 2024 Mar;40(3):545-553. doi: 10.1080/03007995.2024.2313092.
Farge D, Frere C, Connors JM, et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7.
ISSN 
ISSN 
